Works matching IS 01676997 AND DT 2024 AND VI 42 AND IP 4

Results: 15

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else.

Published in:

2024

By:

Kounis, Nicholas G.;
Mplani, Virginia

Publication type:

Letter

Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 442, doi. 10.1007/s10637-024-01454-y

By:

Zhong, Yanqi;
Zhang, Heng;
Wang, Peng;
Zhao, Jing;
Ge, Yuxi;
Sun, Zongqiong;
Wang, Zi;
Li, Jie;
Hu, Shudong

Publication type:

Article

A novel recombinant adenovirus expressing apoptin and melittin genes kills hepatocellular carcinoma cells and inhibits the growth of ectopic tumor.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 428, doi. 10.1007/s10637-024-01453-z

By:

Wu, Jingqiao;
Lan, Zhaoyu;
Li, Xin;
He, Jinling;
Zhang, Dongchao;
Jin, Tianming

Publication type:

Article

Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 369, doi. 10.1007/s10637-024-01452-0

By:

Luo, Panpan;
Guo, Yuge;
He, Yang;
Wang, Chunjiang

Publication type:

Article

Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 405, doi. 10.1007/s10637-024-01451-1

By:

Liu, Hongwei;
Wang, Qianqian;
Lan, Wanying;
Liu, Duanya;
Huang, Jiangang;
Yao, Jie

Publication type:

Article

<sup>177</sup>Lu−SN201 nanoparticle shows superior anti−tumor efficacy over conventional cancer drugs in 4T1 orthotopic model.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 471, doi. 10.1007/s10637-024-01450-2

By:

Lekmeechai, Sujinna;
Pietras, Kristian;
Axelsson, Oskar

Publication type:

Article

Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 361, doi. 10.1007/s10637-024-01449-9

By:

Yokota, Tomoya;
Hamauchi, Satoshi;
Kawakami, Takeshi;
Fushiki, Kunihiro

Publication type:

Article

A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 386, doi. 10.1007/s10637-024-01448-w

By:

Sangha, Randeep;
Jamal, Rahima;
Spratlin, Jennifer;
Kuruvilla, John;
Sehn, Laurie H.;
Beauchamp, Erwan;
Weickert, Michael;
Berthiaume, Luc G.;
Mackey, John R.

Publication type:

Article

Effect of PAWI-2 on pancreatic cancer stem cell tumors.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 353, doi. 10.1007/s10637-024-01447-x

By:

Cashman, John R.;
Cashman, Emily A.

Publication type:

Article

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [<sup>14</sup>C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 343, doi. 10.1007/s10637-024-01446-y

By:

Hanley, Michael J.;
Zhang, Steven;
Griffin, Robert;
Zhu, Sean Xiaochun;
Fram, Robert J.;
Lin, Jianchang;
Venkatakrishnan, Karthik;
Gupta, Neeraj

Publication type:

Article

Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 454, doi. 10.1007/s10637-024-01443-1

By:

Zhang, Jing;
Yang, Wenwei;
Liu, Junbao;
Wang, Nan;
Ren, Zhaoying;
Yang, Tingting;
Xie, Gongli;
Wu, Guifu;
Sun, Yongkun

Publication type:

Article

Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 462, doi. 10.1007/s10637-024-01442-2

By:

Ji, Dongmei;
Shen, Weina;
Li, Ting;
Wang, Huan;
Bai, Jianling;
Cao, Junning;
Hu, Xichun

Publication type:

Article

Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 418, doi. 10.1007/s10637-024-01438-y

By:

Fan, Kai;
Wang, Yueyuan;
Bian, Jiangyujing;
Sun, Yewen;
Dou, Jiaqi;
Pan, Jie;
Yu, Yunli

Publication type:

Article

A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 376, doi. 10.1007/s10637-024-01433-3

By:

Yamamoto, Noboru;
Kuboki, Yasutoshi;
Harano, Kenichi;
Koyama, Takafumi;
Kondo, Shunsuke;
Hagiwara, Akiko;
Suzuki, Noriko;
Fujikawa, Ei;
Toyoizumi, Kiichiro;
Mukai, Mayumi;
Doi, Toshihiko

Publication type:

Article

Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).

Published in:

Investigational New Drugs, 2024, v. 42, n. 4, p. 394, doi. 10.1007/s10637-024-01441-3

By:

Kobayashi, Kazufumi;
Ogasawara, Sadahisa;
Itobayashi, Ei;
Okubo, Tomomi;
Itokawa, Norio;
Nakamura, Kazuyoshi;
Moriguchi, Michihisa;
Watanabe, Shunji;
Ikeda, Masafumi;
Kuroda, Hidekatsu;
Kawaoka, Tomokazu;
Hiraoka, Atsushi;
Yasui, Yutaka;
Kuzuya, Teiji;
Sato, Rui;
Kanzaki, Hiroaki;
Koroki, Keisuke;
Inoue, Masanori;
Nakamura, Masato;
Kiyono, Soichiro

Publication type:

Article